ENTPD1 and neoplasm: This early infiltrate is responsible for the tumor-specific CD8+ T-cell response and anti-tumor activity, as these effects are abrogated by local expression of ATP-degrading enzyme CD39, pharmacological blockage of purinergic receptors, and neutralizing antibody against CD11.